EA033072B1 - Применение антител к семафорину 4d для лечения болезни хантингтона - Google Patents

Применение антител к семафорину 4d для лечения болезни хантингтона

Info

Publication number
EA033072B1
EA033072B1 EA201690813A EA201690813A EA033072B1 EA 033072 B1 EA033072 B1 EA 033072B1 EA 201690813 A EA201690813 A EA 201690813A EA 201690813 A EA201690813 A EA 201690813A EA 033072 B1 EA033072 B1 EA 033072B1
Authority
EA
Eurasian Patent Office
Prior art keywords
semaphorin
huntington
disease
antibodies
treatment
Prior art date
Application number
EA201690813A
Other languages
English (en)
Russian (ru)
Other versions
EA201690813A1 (ru
Inventor
Эрнест С. Смит
Морис Заудерер
Уилльям Дж. Бауэрс
Алан Джонасон
Original Assignee
Вэксинекс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Вэксинекс, Инк. filed Critical Вэксинекс, Инк.
Publication of EA201690813A1 publication Critical patent/EA201690813A1/ru
Publication of EA033072B1 publication Critical patent/EA033072B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EA201690813A 2013-10-21 2014-10-21 Применение антител к семафорину 4d для лечения болезни хантингтона EA033072B1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361893814P 2013-10-21 2013-10-21
US201461979384P 2014-04-14 2014-04-14
US201462012805P 2014-06-16 2014-06-16
PCT/US2014/061592 WO2015061330A1 (en) 2013-10-21 2014-10-21 Use of semaphorin-4d binding molecules for treating neurodegenerative disorders

Publications (2)

Publication Number Publication Date
EA201690813A1 EA201690813A1 (ru) 2016-08-31
EA033072B1 true EA033072B1 (ru) 2019-08-30

Family

ID=52826380

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201690813A EA033072B1 (ru) 2013-10-21 2014-10-21 Применение антител к семафорину 4d для лечения болезни хантингтона

Country Status (19)

Country Link
US (4) US9598495B2 (enExample)
EP (3) EP3060252B1 (enExample)
JP (2) JP6461944B2 (enExample)
KR (4) KR102308493B1 (enExample)
CN (2) CN116966293A (enExample)
AU (3) AU2014340210B2 (enExample)
BR (1) BR112016009047B1 (enExample)
CA (2) CA3193983A1 (enExample)
DK (1) DK3060252T3 (enExample)
EA (1) EA033072B1 (enExample)
ES (2) ES3063301T3 (enExample)
IL (3) IL295045B2 (enExample)
MX (2) MX374708B (enExample)
NZ (1) NZ630892A (enExample)
PL (1) PL3060252T3 (enExample)
PT (1) PT3060252T (enExample)
SG (2) SG11201603167YA (enExample)
WO (1) WO2015061330A1 (enExample)
ZA (1) ZA201602686B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2427212B1 (en) 2009-05-08 2017-08-23 Vaccinex, Inc. Anti-cd100 antibodies and methods for using the same
EA029023B1 (ru) 2011-10-11 2018-01-31 Вэксинекс, Инк. Применение молекул, связывающих семафорин-4d, для модуляции проницаемости гематоэнцефалического барьера
US9708601B2 (en) 2012-04-26 2017-07-18 Vaccinex, Inc. Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
US10494440B2 (en) 2012-05-11 2019-12-03 Vaccinex, Inc. Use of semaphorin-4D binding molecules to promote neurogenesis following stroke
US10626163B2 (en) * 2013-01-25 2020-04-21 Brandeis University Methods of modulating GABAergic inhibitory synapse formation and function
US9243068B2 (en) 2013-06-25 2016-01-26 Vaccinex, Inc. Combination of SEMA-4D inhibitors and immunomodulators to inhibit tumors and metastases
NZ630881A (en) 2013-10-10 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treatment of atherosclerosis
NZ630892A (en) 2013-10-21 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treating neurodegenerative disorders
PT3445397T (pt) 2016-04-22 2023-01-13 Vaccinex Inc Exibição de proteína integral de membrana sobre viriões envelopados extracelulares de poxvírus
SG11201900595YA (en) 2016-08-02 2019-02-27 Vaccinex Inc Improved methods for producing polynucleotide libraries in vaccinia virus/eukaryotic cells
JP7084689B2 (ja) * 2016-12-08 2022-06-15 公益財団法人東京都医学総合研究所 脳組織の異常を伴う非ヒト動物の作製方法およびその利用
KR102533921B1 (ko) * 2017-02-22 2023-05-17 백시넥스 인코포레이티드 신경변성 또는 신경염증성 질환에서의 신경교세포 활성화의 조기 검출
SG11201906404RA (en) 2017-03-20 2019-08-27 Vaccinex Inc Treatment of cancer with a semaphorin-4d antibody in combination with an epigenetic modulating agent
JP7246320B2 (ja) 2017-05-05 2023-03-27 バクシネックス インコーポレーティッド ヒト抗セマフォリン４ｄ抗体
CN109410218B (zh) * 2018-10-08 2020-08-11 百度在线网络技术（北京）有限公司 用于生成车辆损伤信息的方法和装置
EP3693380A1 (en) * 2019-02-11 2020-08-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Dual inhibition of plexin-b1 and plexin-b2
US11597765B2 (en) 2020-06-25 2023-03-07 Vaccinex, Inc. Use of semaphorin-4D binding molecules for the treatment of Rett syndrome
JP7884836B2 (ja) * 2020-12-23 2026-07-06 国立大学法人大阪大学 軟骨・骨・関節疾患の予防または治療用医薬組成物および軟骨・骨・関節疾患の予防または治療用薬剤のスクリーニング方法
MX2024003883A (es) * 2021-09-27 2024-08-28 Vaccinex Inc Perfil predictivo de resultados para el uso de una molecula de union de antisemaforina-4d para el tratamiento de trastornos neurodegenerativos.
US20230101618A1 (en) * 2021-09-27 2023-03-30 Vaccinex, Inc. Predictive outcome profiling for use of an anti-semaphorin-4d binding molecule to treat neurodegenerative disorders
US20230331863A1 (en) 2022-02-13 2023-10-19 Vaccinex, Inc. Combination therapy with semaphorin-4d blockade and htt-lowering agent for treatment of huntington's disease
EP4692124A1 (en) * 2023-04-03 2026-02-11 Sialbio Co., Ltd. Pharmaceutical composition for preventing or treating sjogren's syndrome, containing recombinant anti-semaphorin 4d antibody as active ingredient
CN117924494B (zh) * 2024-01-23 2025-02-25 首都医科大学附属北京积水潭医院 特异性结合sema4d的抗原结合蛋白及其应用
WO2026030311A1 (en) * 2024-07-29 2026-02-05 Vaccinex, Inc. Use of semaphorin-4d inhibitory molecules to treat cognitive impairment

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130095118A1 (en) * 2011-10-11 2013-04-18 Vaccinex, Inc. Use of Semaphorin-4D Binding Molecules for Modulation of Blood Brain Barrier Permeability

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ201918A (en) 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5070192A (en) 1988-03-23 1991-12-03 The Johns Hopkins University Cloned human topoisomerase i: cdna expression, and use for autoantibody detection
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6497872B1 (en) 1991-07-08 2002-12-24 Neurospheres Holdings Ltd. Neural transplantation using proliferated multipotent neural stem cells and their progeny
FR2686087A1 (fr) 1992-01-13 1993-07-16 Inst Nat Sante Rech Med Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications.
US5639856A (en) 1993-09-13 1997-06-17 The Regents Of The University Of California Semaphorin gene family
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US6576754B2 (en) 1995-11-09 2003-06-10 Dana-Farber Cancer Institute CD100 antigen and uses therefor
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
DE69829891T2 (de) 1997-04-07 2005-10-06 Genentech, Inc., South San Francisco Anti-VEGF Antikörper
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
EP0973916A1 (en) 1997-04-11 2000-01-26 Dendreon Corporation Composition and method for inducing an immune response against tumour-related antigens
EP0892047A3 (de) 1997-07-09 2000-03-08 Hoechst Marion Roussel Deutschland GmbH Humanes und murines Semaphorin L
US5968829A (en) 1997-09-05 1999-10-19 Cytotherapeutics, Inc. Human CNS neural stem cells
US6638501B1 (en) 1997-09-29 2003-10-28 Neurospheres Holdings Ltd. Use of multipotent neural stem cell progeny to augment non-neural tissues
US5958767A (en) 1998-08-14 1999-09-28 The Children's Medical Center Corp. Engraftable human neural stem cells
ATE407206T1 (de) 1998-11-10 2008-09-15 Univ Rochester Methoden zu herstellung von genbanken
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
JP3787473B2 (ja) 1999-11-30 2006-06-21 独立行政法人科学技術振興機構 セマフォリン受容体
AU2913801A (en) 1999-12-23 2001-07-03 Cornell Research Foundation Inc. A method for isolating and purifying multipotential neural progenitor cells and multipotential neural progenitor cells
US6635742B1 (en) 2000-01-25 2003-10-21 Nuvelo, Inc. Antibodies specific for semaphorin-like polypeptides
IL159177A0 (en) 2001-06-20 2004-06-01 Prochon Biotech Ltd Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
EP1365018A1 (en) 2002-05-23 2003-11-26 Institut National De La Sante Et De La Recherche Medicale (Inserm) CD100 semaphorin in myelination
CA2487932A1 (en) 2002-05-30 2003-12-11 Macrogenics, Inc. Cd16a binding proteins and use for the treatment of immune disorders
EP1442749A1 (en) 2003-01-31 2004-08-04 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system
RS20150135A1 (sr) 2003-05-30 2015-08-31 Genentech Inc. Tretman sa anti-vegf antitelima
CN1922208A (zh) 2003-12-11 2007-02-28 健泰科生物技术公司 用于抑制c－met二聚化及活化的方法和组合物
ME01803B (me) 2004-08-05 2010-12-31 Genentech Inc Humanizovani anti-cmet antagonisti
US20060147449A1 (en) 2004-11-15 2006-07-06 Brass Lawrence F Method of using CD100 (or Sema4D) to mediate platelet activation and inflammatory responses
CA2603780A1 (en) 2005-04-07 2006-10-19 Novartis Vaccines And Diagnostics, Inc. Sema4d in cancer diagnosis, detection and treatment
JP2007308465A (ja) 2006-05-15 2007-11-29 Boehringer Ingelheim Internatl Gmbh 炎症性疾患、自己免疫疾患又は骨吸収異常の治療方法
WO2008100995A1 (en) 2007-02-14 2008-08-21 Vaccinex, Inc. Humanized anti-cd100 antibodies
US20090181035A1 (en) 2008-01-10 2009-07-16 Genentech, Inc. Plexind1 agonists and their use
EP2427212B1 (en) 2009-05-08 2017-08-23 Vaccinex, Inc. Anti-cd100 antibodies and methods for using the same
AU2010248761B2 (en) 2009-05-15 2016-02-11 Irx Therapeutics, Inc. Vaccine immunotherapy
WO2011063415A2 (en) * 2009-11-23 2011-05-26 Afraxis, Inc. Methods for treating mild cognitive impairment
CA2802376A1 (en) 2010-06-14 2011-12-22 Vaccinex, Inc. Anti-vegf antibodies and uses thereof
EP2711023B1 (en) 2011-05-13 2017-07-12 National University Corporation Tokyo Medical and Dental University Osteogenesis promoter
US8790652B2 (en) 2011-12-06 2014-07-29 Vaccinex, Inc. Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis
US9090709B2 (en) 2012-03-28 2015-07-28 Vaccinex, Inc. Anti-SEMA4D antibodies and epitopes
US9708601B2 (en) 2012-04-26 2017-07-18 Vaccinex, Inc. Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
US10494440B2 (en) * 2012-05-11 2019-12-03 Vaccinex, Inc. Use of semaphorin-4D binding molecules to promote neurogenesis following stroke
US9243068B2 (en) 2013-06-25 2016-01-26 Vaccinex, Inc. Combination of SEMA-4D inhibitors and immunomodulators to inhibit tumors and metastases
NZ630881A (en) 2013-10-10 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treatment of atherosclerosis
NZ630892A (en) 2013-10-21 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treating neurodegenerative disorders
PT3445397T (pt) 2016-04-22 2023-01-13 Vaccinex Inc Exibição de proteína integral de membrana sobre viriões envelopados extracelulares de poxvírus
SG11201900595YA (en) 2016-08-02 2019-02-27 Vaccinex Inc Improved methods for producing polynucleotide libraries in vaccinia virus/eukaryotic cells
KR102533921B1 (ko) 2017-02-22 2023-05-17 백시넥스 인코포레이티드 신경변성 또는 신경염증성 질환에서의 신경교세포 활성화의 조기 검출

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130095118A1 (en) * 2011-10-11 2013-04-18 Vaccinex, Inc. Use of Semaphorin-4D Binding Molecules for Modulation of Blood Brain Barrier Permeability

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LYKETSOS et al. Neuropsychiatric symptoms in Alzheimer's disease. Alzheimers Dement. 2011, Vol. 7(5), p. 532-9. PDF file: pg 1-14. Entire documentation, especially Abstract, and pg 2, para 1-3. *
NUBER et al. Neurodegeneration and Motor Dysfunction in a Conditional Model of Parkinson's Disease. J Neurosci. 2008, Vol. 28(10), p. 2471-84. Entire documentation, especially abstract *
SMITH et al. SEMA4D compromises blood-brain barrier, activates microglia, and inhibits remyelination in neurodegenerative disease. Neurobiol Dis, 2015 Jan. Vol 73, p. 254-268. Entire documentation, especially abstract *

Also Published As

Publication number Publication date
AU2014340210B2 (en) 2019-08-08
KR102308493B1 (ko) 2021-10-07
BR112016009047A2 (pt) 2017-09-19
NZ630892A (en) 2016-03-31
US20190322757A1 (en) 2019-10-24
PL3060252T3 (pl) 2020-05-18
WO2015061330A1 (en) 2015-04-30
US9249227B2 (en) 2016-02-02
AU2021202095A1 (en) 2021-05-06
IL245089A0 (en) 2016-06-30
EP4717270A3 (en) 2026-07-01
AU2019257379A1 (en) 2019-11-14
SG11201603167YA (en) 2016-05-30
EP3060252A4 (en) 2017-06-07
ZA201602686B (en) 2020-11-25
EP3639853C0 (en) 2026-01-21
EP4717270A2 (en) 2026-04-01
ES3063301T3 (en) 2026-04-16
US10800853B2 (en) 2020-10-13
IL295045B2 (en) 2024-04-01
AU2014340210A1 (en) 2016-05-05
CA3193983A1 (en) 2015-04-30
US9598495B2 (en) 2017-03-21
US10385136B2 (en) 2019-08-20
KR20210118246A (ko) 2021-09-29
US20170198053A1 (en) 2017-07-13
DK3060252T3 (da) 2020-03-16
JP6875363B2 (ja) 2021-05-26
KR20230159633A (ko) 2023-11-21
CN116966293A (zh) 2023-10-31
IL275720B (en) 2022-09-01
EP3060252A1 (en) 2016-08-31
EP3060252B1 (en) 2019-12-11
US20150353641A1 (en) 2015-12-10
BR112016009047B1 (pt) 2024-02-06
ES2773961T3 (es) 2020-07-15
MX2016005050A (es) 2016-08-17
SG10201707786QA (en) 2017-10-30
CA2927841A1 (en) 2015-04-30
US20150110800A1 (en) 2015-04-23
JP6461944B2 (ja) 2019-01-30
KR102602502B1 (ko) 2023-11-14
EA201690813A1 (ru) 2016-08-31
PT3060252T (pt) 2020-03-04
CN106029093B (zh) 2023-03-28
MX2020009260A (es) 2020-10-01
KR20220110853A (ko) 2022-08-09
IL295045B1 (en) 2023-12-01
IL295045A (en) 2022-09-01
AU2019257379B2 (en) 2021-04-01
JP2019059786A (ja) 2019-04-18
AU2021202095B9 (en) 2023-11-09
AU2021202095B2 (en) 2023-11-02
MX374708B (es) 2025-03-06
IL245089B (en) 2020-10-29
KR20160065981A (ko) 2016-06-09
CA2927841C (en) 2023-05-23
CN106029093A (zh) 2016-10-12
EP3639853A1 (en) 2020-04-22
JP2017502920A (ja) 2017-01-26
IL275720A (en) 2020-08-31
EP3639853B1 (en) 2026-01-21

Similar Documents

Publication Publication Date Title
EA201690813A1 (ru) Применение семафорин-4d-связывающих молекул для лечения нейродегенеративных нарушений
BR112017009264A2 (pt) proteína de ligação a epítopo ou um fragmento da mesma e imunoglobulina heterodimérica ou um fragmento da mesma
AU2018256487A1 (en) Antibodies that bind to TL1A and their uses
GT201300149A (es) Proteinas de union al tnf-a
ES2621874T3 (es) Anticuerpos para MUC16 y métodos de uso de los mismos
PE20200294A1 (es) Anticuerpos que se unen especificamente a pd-1 y metodos de uso
EA201490053A1 (ru) Антитела, которые связываются с ox40, и их применение
JP2013506675A5 (enExample)
EA201990171A1 (ru) Биспецифичное антитело против egfr и против cd3 и его применения
ES2639026T3 (es) Anticuerpos totalmente humanos específicos para CADM1
UA116194C2 (uk) Антитіло, яке специфічно зв'язується з людським альфа-синуклеїном
ES2776179T3 (es) Anticuerpos dirigidos contra determinantes de la superficie de S. aureus
EA201792657A1 (ru) Связывающие lag-3 молекулы и способы их применения
UY33407A (es) Anticuerpos específicos del factor gdf8 humano
EA201190132A1 (ru) Гуманизированные антитела, связывающиеся с cd19, и их применение
NZ706377A (en) Il-6 antagonists and uses thereof
CL2012000229A1 (es) Anticuerpo humano aislado o un fragmento del mismo de unión al antígeno, que se une específicamente a la angiopoyetina-2 humana (hang-2) pero que no se une sustancialmente a la hang-1; composición farmacéutica que lo comprende; y su uso para el tratamiento de un tumor, hipertensión, diabetes, edema, enfermedad renal u ocular.
PE20131403A1 (es) Anticuerpos anti-ox40 y metodos de uso de los mismos
PE20150023A1 (es) Proteinas de union a antigeno st2
EA201070730A1 (ru) Гуманизированные антитела, специфичные к фактору фон виллебранда
EA201400390A1 (ru) Антитела к tl1a и их применение
HRP20230844T1 (hr) Anti-cd3 antitijela, bispecifične molekule koje vežu antigen koji veže cd3 i cd20, i njihove upotrebe
EA201591806A1 (ru) Лечение и профилактика острой почечной недостаточности с применением анти-альфа-v-бета-5 антител
JOP20200161B1 (ar) أجسام مضادة أحادية النسيلة وطرق استخدامها
AR117735A1 (es) ANTICUERPOS MONOCLONALES QUE SE UNEN ESPECÍFICAMENTE A LA REGIÓN b DE LA FAMILIA TRBV-9 DEL RECEPTOR DE CÉLULAS T HUMANO, Y LOS MÉTODOS PARA SU USO